Related references
Note: Only part of the references are listed.Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
Seongseok Yun et al.
LEUKEMIA (2021)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelody-splastic syndromes and acute myeloid leukemia
Nabih Maslah et al.
HAEMATOLOGICA (2020)
Integrating the Immunome in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design
Susann Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
Lionel Ades et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genetic basis of myelodysplastic syndromes
Seishi Ogawa
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2020)
Telomerase: Key regulator of inflammation and cancer
Lele Wu et al.
PHARMACOLOGICAL RESEARCH (2020)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
David A. Sallman et al.
BLOOD (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
Anne Sophie Kubasch et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia
Stephane De Botton et al.
BLOOD (2020)
Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Michael R. Savona et al.
BLOOD (2020)
Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum
Alain Sarasin et al.
BLOOD (2019)
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
Jan Philipp Bewersdorf et al.
LEUKEMIA (2019)
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
David A. Sallman et al.
LEUKEMIA RESEARCH (2019)
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
N. Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Guillermo Garcia-Manero et al.
LANCET HAEMATOLOGY (2019)
An update on the biology and management of dyskeratosis congenita and related telomere biology disorders
Marena R. Niewisch et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib plus Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Guillermo Garcia-Manero et al.
BLOOD (2019)
Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition
Tamara K. Moyo et al.
BLOOD (2019)
HDAC Inhibitors in Acute Myeloid Leukemia
Edurne San Jose-Eneriz et al.
CANCERS (2019)
Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features
Valeria Visconte et al.
CANCERS (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myelodysplasies (GFM)
Thomas Cluzeau et al.
BLOOD (2019)
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine
Guillermo Garcia-Manero et al.
BLOOD (2019)
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
David A. Sallman et al.
BLOOD (2019)
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Guillaume Richard-Carpentier et al.
BLOOD (2019)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Amer M. Zeidan et al.
BLOOD (2019)
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Uma Borate et al.
BLOOD (2019)
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
Jorge E. Cortes et al.
BLOOD (2019)
Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
Amer M. Zeidan et al.
BLOOD (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Shwachman-Diamond Syndrome: Molecular Mechanisms and Current Perspectives
Valentino Bezzerri et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
Anticancer effects of anti-CD47 immunotherapy in vivo
Kristina Iribarren et al.
ONCOIMMUNOLOGY (2019)
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies
Michael R. Savona et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
Maro Ohanian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML
Jorge E. Cortes et al.
BLOOD (2018)
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Ronan T. Swords et al.
BLOOD (2018)
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Amer M. Zeidan et al.
CLINICAL CANCER RESEARCH (2018)
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience
Alecia S. Folkes et al.
CURRENT OPINION IN ONCOLOGY (2018)
Effects of 5-Aza-2-deoxycytidine (decitabine) on gene expression
Ratnam S. Seelan et al.
DRUG METABOLISM REVIEWS (2018)
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
Shyamala C. Navada et al.
LEUKEMIA RESEARCH (2018)
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Michael Seiler et al.
NATURE MEDICINE (2018)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji et al.
LANCET HAEMATOLOGY (2018)
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia
Guillermo Garcia-Manero et al.
LEUKEMIA RESEARCH (2018)
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
Johanna S. Ungerstedt
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study
Courtney D. DiNardo et al.
BLOOD (2018)
A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
Guillermo Garcia-Manero et al.
BLOOD (2018)
Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors
Marjorie Poggi et al.
HAEMATOLOGICA (2017)
Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology
Peter L. Greenberg et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors
Marjorie Poggi et al.
HAEMATOLOGICA (2017)
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
James A. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2017)
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≤ 30% blasts
G. Garcia-Manero et al.
LEUKEMIA (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Ting Han et al.
SCIENCE (2017)
Clonal evolution in myelodysplastic syndromes
Pedro da Silva-Coelho et al.
NATURE COMMUNICATIONS (2017)
Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
Toshio Asayama et al.
ONCOTARGET (2017)
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells
Kumiko Ueda et al.
DRUG METABOLISM AND PHARMACOKINETICS (2017)
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents
Moreno Festuccia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Tumor evolution: Linear, branching, neutral or punctuated?
Alexander Davis et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
Epigenetics in normal and malignant hematopoiesis: An overview and update 2017
Susumu Goyama et al.
CANCER SCIENCE (2017)
Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
CANCER (2017)
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Thomas Prebet et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults
Daria V. Babushok et al.
LEUKEMIA & LYMPHOMA (2016)
Increased DNA methylation of Dnmt3b targets impairs leukemogenesis
Isabell Schulze et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Sai Krishna Athuluri-Divakar et al.
CELL (2016)
Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells
Didem Ozkazanc et al.
IMMUNOLOGY (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero et al.
LANCET ONCOLOGY (2016)
A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome
Mathew A. Cherian et al.
LEUKEMIA & LYMPHOMA (2016)
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins
Stanley Chun-Wei Lee et al.
NATURE MEDICINE (2016)
Therapeutic targeting of splicing in cancer
Stanley Chun-Wei Lee et al.
NATURE MEDICINE (2016)
Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment
Guillermo Garcia-Manero et al.
BLOOD (2016)
Hereditary Predispositions to Myelodysplastic Syndrome
Sarah A. Bannon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
David Sanford et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
I-K Park et al.
LEUKEMIA (2015)
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
A. G. Dinmohamed et al.
LEUKEMIA (2015)
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
T. Bernal et al.
LEUKEMIA (2015)
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes
Talha Badar et al.
LEUKEMIA RESEARCH (2015)
Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin
Yuting Kuang et al.
MOLECULAR ONCOLOGY (2015)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
Germ line ETV6 mutations in familial thrombocytopenia and hematologic malignancy
Michael Y. Zhang et al.
NATURE GENETICS (2015)
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
Lewis R. Silverman et al.
HEMATOLOGICAL ONCOLOGY (2015)
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
Aristoteles Giagounidis et al.
ANNALS OF HEMATOLOGY (2014)
The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Fang Fang et al.
CLINICAL CANCER RESEARCH (2014)
Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?
Carolyn S. Grove et al.
DISEASE MODELS & MECHANISMS (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts
Pragya Srivastava et al.
LEUKEMIA RESEARCH (2014)
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Ana C. Anderson
CANCER IMMUNOLOGY RESEARCH (2014)
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Naval Daver et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
Il-Kyoo Park et al.
BLOOD (2013)
The genetic basis of myelodysplasia and its clinical relevance
Mario Cazzola et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
Rami S. Komrokji et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
The development and application of small molecule modulators of SF3b as therapeutic agents for cancer
Thomas R. Webb et al.
DRUG DISCOVERY TODAY (2013)
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
Maria Teresa Voso et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
David A. Macdonald et al.
LEUKEMIA & LYMPHOMA (2013)
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy
Esther N. Oliva et al.
LEUKEMIA & LYMPHOMA (2013)
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Mikkael A. Sekeres et al.
BLOOD (2012)
Defects in spliceosomal machinery: a new pathway of leukaemogenesis
Jaroslaw P. Maciejewski et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies
Gandhi Damaj et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions
Samuel Quentin et al.
BLOOD (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
Lewis R. Silverman et al.
CANCER (2011)
The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region
Eric G. Folco et al.
GENES & DEVELOPMENT (2011)
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Lars Mollgard et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
M. J. Walter et al.
LEUKEMIA (2011)
Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine
Shinsuke Ito et al.
SCIENCE (2011)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
Lionel Ades et al.
BLOOD (2009)
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Omar Abdel-Wahab et al.
BLOOD (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Mamta Tahiliani et al.
SCIENCE (2009)
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Carlo Stresemann et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47
Deborah Hatherley et al.
MOLECULAR CELL (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
Ivana Gojo et al.
BLOOD (2007)
Decitabine - Bedside to bench
Yasuhiro Oki et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey
Manuela Germeshausen et al.
BLOOD (2007)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination moth all-trans retinoic acid in patients with acute myeloid leukemia
A Kuendgen et al.
CANCER (2006)
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia
LY Shih et al.
LEUKEMIA (2004)
Mutations in SBDS are associated with Shwachman-Diamond syndrome
GRB Boocock et al.
NATURE GENETICS (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
